ArticleInfluenza and other respiratory viruses2026
The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019-2023.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protecting infants from RSV: cost-effectiveness of nirsevimab in a real-world study from Chile.Lancet regional health. Americas · 2026Article
- Correction to "The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019-2023".Influenza and other respiratory viruses · 2026Article
- The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019-2023.Influenza and other respiratory viruses · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
Abstract
backgroundFrom 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019 to 2023. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of interventions such as passive immunization, vaccines, and antivirals. METHODOLOGY: All RSV sequence data submitted to GISAID by WHO project countries from January 1, 2019, to December 31, 2023, was analyzed to evaluate progress in sequencing, lineage distribution, and RSV fusion (F) protein diversity.
resultsFrom 2019 to 2023, 44,571 RSV sequences were submitted to GISAID, including 61% RSV-A and 39% RSV-B, with 34% being whole-genome sequences. WHO project countries contributed 13,280 sequences (30%), with submissions increasing from 158 in 2020 to 3716 in 2023. Median data submission time improved from 1116 days in 2020 to 206 days in 2023. The dominant lineage detected was A.D.1 (20%) for RSV-A and B.D.4.1.1 (29%) for RSV-B. The F protein sequences showed high amino acid conservation: 97% for RSV-A and 96% for RSV-B.
conclusionSubstantial progress has been made in RSV genomic sequencing capacities in WHO project countries as seen by the increased submissions and improved timeliness of sequence data. RSV exhibited co-circulating lineages (RSV-A and RSV-B) with low F protein diversity. It is important to sustain and further strengthen RSV sequencing capacities in all WHO regions as part of the ongoing WHO Global Genomic Surveillance strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.